Proof of Concept Study to Evaluate Safety and Efficacy of LME636 in the Treatment of Acute Anterior Uveitis

Phase 2

Completed

• Conditions: Acute Anterior Uveitis
• Interventions: Drug: Dexamethasone 0.1% ophthalmic solution; Drug: LME636 60 mg/mL ophthalmic solution; Drug: LME636 Vehicle

• Registration Number: NCT02482129
• Lead Sponsor: Alcon Research

Brief Summary

The purpose of the study is to determine whether topical ocular administration of LME636 60 mg/mL is efficacious in resolving the ocular inflammation in the anterior chamber (AC) associated with acute anterior uveitis (AAU).

Detailed Description

Eligible subjects will be randomized to LME636 or Dexamethasone in a 3:1 ratio at the time they present to the trial site with the AAU flare and will enter treatment for 28 full days. Subjects with worsening disease from Visit 2/Day 4 onward or subjects without improvement after 14 days of treatment will be discontinued from treatment, unmasked and treated with a rescue regimen at the discretion of the investigator.

Study Timeline

• Study First Submitted: 2015-06-23
• Study First Submitted QC: 2015-06-25
• Study First Posted: 2015-06-26
• Study Start: 2015-07-17
• Primary Completion: 2016-03-21
• Study Completion: 2016-03-21
• Disposition First Submitted: 2017-01-13
• Disposition First Submitted QC: 2017-01-13
• Disposition First Posted: 2017-01-16
• Status Verified: 2017-07
• Results First Submitted: 2017-07-28
• Results First Submitted QC: 2017-07-28
• Results First Posted: 2017-08-28
• Last Update Submitted: 2018-05-31
• Last Update Posted: 2018-07-02

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 45

Inclusion Criteria

• Provide written informed consent.
• Diagnosis of non-infectious AAU in at least 1 eye.
• Anterior chamber cell score of 2+ or 3+ as per Standardization of Uveitis Nomenclature (SUN) in at least one eye.
• Able to communicate well with the Investigator, to understand and comply with the requirements of the study.
• Other protocol-specified inclusion criteria may apply.

Exclusion Criteria

• Women of child-bearing potential unwilling to use effective contraception methods as defined in the protocol.
• AC cell score of 4+ (SUN) or hypopyon.
• Onset of anterior uveitis more than 2 weeks prior to enrollment in the study.
• Presence of intermediate-, posterior-, or panuveitis in either eye.
• Administration of stable doses >10 mg daily systemic prednisone or corticosteroids as described in the protocol.
• Recurrent corneal abrasion or ulceration in either eye (past or present).
• Tuberculosis (past or present).
• Other protocol-specified exclusion criteria may apply.

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: PARALLEL

Arm && Interventions

Group	Intervention	Description
Dexamethasone	Dexamethasone 0.1% ophthalmic solution	Dexamethasone 0.1% ophthalmic solution, maximum drop frequency administered for 2 weeks, followed by a tapering for 2 weeks (Weeks 3 and 4)
LME636	LME636 60 mg/mL ophthalmic solution	LME636 60 mg/mL ophthalmic solution, maximum drop frequency administered for 2 weeks, followed by a tapering for 1 week (Week 3) and 1 week of masked Vehicle administration (Week 4)
LME636	LME636 Vehicle	LME636 60 mg/mL ophthalmic solution, maximum drop frequency administered for 2 weeks, followed by a tapering for 1 week (Week 3) and 1 week of masked Vehicle administration (Week 4)

Primary Outcome Measures

Name	Time	Method
Number of Responders at Day 15	Baseline (Day 1), Day 15	Response was defined as a two-step decrease or more from baseline in Anterior Chamber (AC) Cell Grade as per Standardization of Uveitis Nomenclature (SUN). Baseline was defined as the measurement taken before drug administration on Day 1. Subjects receiving rescue treatment on or before Day 15 were considered non-responders. Only one eye contributed to the analysis.
Mean Best Corrected Visual Acuity (BCVA) at Each Visit	Baseline (Day 1), Day 4, Day 8, Day 15, Day 22, Day 29	Visual Acuity (VA) with the subject's best spectacles or other visual corrective devices was measured using an Early Treatment of Diabetic Retinopathy Study (ETDRS) or Snellen visual acuity chart and reported in letters read correctly. An increase (gain) in letters read indicates improvement. Only one eye contributed to the analysis.
Mean Intraocular Pressure (IOP) at Each Visit	Baseline (Day 1), Day 4, Day 8, Day 15, Day 22, Day 29	IOP (fluid pressure inside the eye) was assessed using Goldmann applanation tonometry or Tonopen and reported in millimeters mercury (mmHg). A higher IOP can be a greater risk factor for developing glaucoma or glaucoma progression (leading to optic nerve damage). Only one eye contributed to the analysis.
Number of Subjects With Increase From Baseline in Slit Lamp Parameters at Any Post-Treatment Visit	Baseline (Day 1), Day 4, Day 8, Day 15, Day 22, Day 29	Slit-lamp biomicroscopy (examination) was performed to evaluate the anterior segment of the eye, including lids/lashes, conjunctiva, cornea, anterior chamber (cells and flare), iris, and lens. Ocular signs were categorized as Aqueous Flare, Aqueous Inflammatory Cell Grade, Keratic Precipitates, Lens, Limbal Injection, Status of Lens, Peripheral Anterior Synechia, and Posterior Synechia. An increase indicates worsening. Only one eye contributed to the analysis.
Number of Subjects With an Increase From Baseline in Dilated Fundus Parameters at Any Post-Treatment Visit	Baseline (Day 1), Day 4, Day 8, Day 15, Day 22, Day 29	The dilated fundus examination was performed to evaluate the health of the vitreous, optic disc, retinal vessels, macula, and retinal periphery. An increase indicates worsening. Only one eye contributed to the analysis.

Secondary Outcome Measures

Name	Time	Method
Number of Subjects With IOP Change From Baseline to Last On-Treatment Assessment	Baseline (Day 1), Up to Day 29	IOP was assessed using Goldmann applanation tonometry or Tonopen and reported in mmHg. A higher IOP can be a greater risk factor for developing glaucoma or glaucoma progression (leading to optic nerve damage). Only one eye contributed to the analysis.
Mean Change From Baseline in BCVA at Each Visit	Baseline (Day 1), Day 4, Day 8, Day 15, Day 22, Day 29	Visual Acuity (VA) was measured with the participant's best spectacles or other visual corrective device in place using an ETDRS or Snellen visual acuity chart. Improvement of BCVA was defined as an increase (gain) in letters read from the baseline assessment. Only one eye contributed to the analysis.
Time-to-Response	Baseline (Day 1), Up to Day 15	Time-to-Response was defined as the number of days from baseline to the first scheduled visit when a two-step decrease or more from baseline in AC Cell Grade (as per SUN) was observed. Time-to-Response is reported as number of subjects presenting time-to-response by visit. Only one eye contributed to the analysis.
Use of Rescue Treatment	Day 4, Day 8, Day 15	Use of rescue treatment is presented as the number of subjects with first use of rescue treatment by visit. Subjects receiving rescue medication were not considered withdrawn and the collection of data continued after discontinuation of study treatment. Only one eye contributed to the analysis.
Mean Serum Concentration of Total LME636 at Each Visit	Baseline (Day 1), Day 4, Day 8, Day 15, Day 22, Day 29	Serum concentrations at each collection time point were quantitated, where possible, using a validated immunoassay method. Concentrations below the limit of quantification (BLQ), defined as 0.25 ng/mL, were reported as NA with no imputation for missing data.
Number of Subjects With Anti-LME636 Antibodies Present at Each Visit	Day 1, Day 4, Day 8, Day 15, Day 22, Day 29	Serum samples were collected and assessed for anti-LME636 antibodies. Samples collected from subjects in the LME636 dose group were analyzed for anti-LME636 antibodies. For subjects in the dexamethasone group, only the samples collected on Day 1 (ie, prior to the start of treatment) were analyzed for anti-LME636 antibodies.